IP Library Granted Patent US 12,344,884
Granted Patent B2
US 12,344,884 · App. 17/255,500 · Granted Jul 1, 2025

Sample preparation method and system

Inventors: Matthias Jost (San Diego, CA); Barbara L. Eaton (San Diego, CA); Ankur Shah (San Diego, CA)
Assignee: GEN-PROBE INCORPORATED
C12Q1/6806C12N15/1006C12Q1/689
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,344,884
App. No.
17/255,500
Granted
Jul 1, 2025
Kind
B2
Abstract

Method of preparing a biological sample appropriate for use in a subsequent in vitro nucleic acid amplification reaction. A biological sample is combined with an alkaline composition that lyses cells and denatures DNA to create a first liquid composition. The first liquid composition is then mixed with a buffer, a detergent, and a solid support that captures DNA to create a second liquid composition. The buffer, detergent, and solid support can be delivered as components of a single reagent. Captured DNA strands can be used as templates in subsequently performed nucleic acid amplification and detection reactions with improved sensitivity.

Claims (26)

1. A method of processing a biological sample, the method comprising the steps of:

(a) mixing the biological sample with an alkaline composition that lyses cells and denatures DNA to create a first liquid composition,

wherein the first liquid composition has a pH in the range of from pH 12.0 to pH 13.5, and

wherein the first liquid composition is free of detergents;

(b) mixing the first liquid composition with a pH buffered detergent reagent to create a second liquid composition having a pH lower than pH 9.5,

wherein the pH buffered detergent reagent comprises a pH buffer, a detergent, and a solid support particle that captures DNA; and

(c) isolating the solid support particle, and any DNA captured thereon, from the second liquid composition.

2. The method of claim 1 , wherein the biological sample comprises viable bacterial cells, and wherein the method further comprises the step of culturing the viable bacterial cells to increase the number of bacterial cells.

3. The method of claim 1 , wherein the second liquid composition has a pH in the range of from pH 8.0 to pH 9.2.

4. The method of claim 1 , wherein each of steps (a)-(c) is conducted onboard an automated instrument that comprises a robotic fluid transfer device.

5. The method of claim 4 , further comprising the step of (d) performing an in vitro nucleic acid amplification reaction using DNA isolated in step (c) as templates, and detecting products of the in vitro nucleic acid amplification reaction.

6. The method of claim 5 , wherein detecting products of the in vitro nucleic acid amplification reaction indicates the presence of a species of Gram-positive bacteria in the biological sample.

7. The method of claim 5 , wherein step (d) is carried out onboard the automated instrument.

8. The method of claim 4 , wherein step (a) comprises combining the biological sample and the alkaline composition in a reaction vessel to create the first liquid composition, wherein step (b) comprises adding the pH buffered detergent reagent to the reaction vessel containing the first liquid composition to create the second liquid composition, and wherein each of steps (a) and (b) is performed using the robotic fluid transfer device of the automated instrument.

9. The method of claim 8 , wherein the automated instrument further comprises a transport mechanism that moves the reaction vessel from one position within the automated instrument to a different position within the automated instrument.

10. The method of claim 9 , wherein after step (b) and before step (c) there is the step of incubating the first liquid composition for a period of time between 1 minute and 10 minutes.

11. The method of claim 10 , wherein the incubating step comprises heating the first liquid composition.

12. The method of claim 10 , wherein the incubating step comprises transporting the reaction vessel from a first position in the automated instrument to a second position in the automated instrument, and wherein the second position in the automated instrument is at a temperature higher than the temperature at the first position in the automated instrument.

13. The method of claim 1 , wherein the solid support particle comprises a magnetically attractable particle.

14. The method of claim 1 , wherein the solid support particle in step (b) is a solid support particle that captures DNA independent of base sequence, and wherein step (c) comprises washing the solid support particle to remove any material not immobilized thereon, and then retaining the solid support particle after washing, whereby captured DNA is isolated.

15. The method of claim 1 , wherein the alkaline composition comprises a strong base in aqueous solution at a concentration of from 0.1 N to 2.2 N.

16. The method of claim 15 , wherein the pH of the first liquid composition is in the range of from pH 12.5 to pH 13.2.

17. The method of claim 15 , wherein the pH of the second liquid composition is in the range of from pH 7.6 to pH 8.8.

18. The method of claim 15 , wherein the alkaline composition comprises the strong base at a concentration of from 1.0 N to 1.7 N.

19. The method of claim 15 , wherein the strong base is selected from the group consisting of NaOH, KOH, and LiOH.

20. The method of claim 1 , wherein all steps are carried out under automated process control.

Assignments (2)
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
SECURITY INTEREST Recorded Oct 12, 2021
From: HOLOGIC, INC.; FAXITRON BIOPTICS, LLC; BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 057787/0526 →
Continuity (2)
Provisional Application 62691478 · Jun 28, 2018
Related Publication 20210269854A1 · Sep 2, 2021
References Cited (58)
US 4965188A · Mullis et al. · 1990 [cited by applicant]
US 5399491A · Kacian et al. · 1995 [cited by applicant]
US 5455166A · Walker · 1995 [cited by applicant]
US 5472840A · Stefano · 1995 [cited by applicant]
US 7510837B2 · Gao et al. · 2009 [cited by applicant]
US 8258281B2 · Vuylsteke et al. · 2012 [cited by applicant]
US 8420317B2 · Gao et al. · 2013 [cited by applicant]
US 20020019007A1 · Jensen · 2002 [cited by examiner]
US 20040229268A1 · Hogan et al. · 2004 [cited by applicant]
US 20050118593A1 · Potocki et al. · 2005 [cited by applicant]
US 20070031880A1 · Lou · 2007 [cited by examiner]
US 20120058011A1 · Wirbisky et al. · 2012 [cited by applicant]
US 20120071360A1 · Gao · 2012 [cited by examiner]
US 20130132006A1 · Gwynn · 2013 [cited by examiner]
US 20140205996A1 · Lizzi et al. · 2014 [cited by applicant]
US 20150218653A1 · Sprenger-Haussels et al. · 2015 [cited by applicant]
US 20180163259A1 · Peterson et al. · 2018 [cited by applicant]
CA 2679843C · 2018 [cited by applicant]
EP 0135159A2 · 1985 [cited by applicant]
EP 0270017A2 · 1988 [cited by applicant]
EP 0525882B1 · 2004 [cited by applicant]
JP 2006517225A · 2006 [cited by applicant]
JP 2014045689A · 2006 [cited by applicant]
WO 2004072229A2 · 2004 [cited by applicant]
WO WO2006073497A1 · 2006 [cited by applicant]
WO WO2011083076A1 · 2011 [cited by applicant]
WO WO2014144174A1 · 2014 [cited by applicant]
WO WO2017088169A1 · 2017 [cited by applicant]
Belgrader et al., BioTechniques 19(3): 426-432 (Year: 1995). [cited by examiner]
Merel et al.Clinical Chemistry42(8) : 1285 (Year: 1996). [cited by examiner]
Mischiati et al., BioTechniques 15(1) :146 (Year: 1993). [cited by examiner]
PCT International Search Report and Written Opinion, International Application No. PCT/US2019/037245, Sep. 3, 2019. [cited by applicant]
PCT International Preliminary Report on Patentability, International Application No. PCT/US2019/037245, Dec. 29, 2020. [cited by applicant]
EPO Communication pursuant to Article 94(3) EPC, European Application No. 19734637.2, Jan. 31, 2022. [cited by applicant]
JPO Official Action, Japanese Patent Application No., 2020-572965, Jan. 17, 2024. [cited by applicant]
JPO Official Action, Japanese Patent Application No., 2020-572965, Jun. 15, 2023. [cited by applicant]
Lizardi et al., BioTechnology 6:1197 (1988). [cited by applicant]
Birnboim and Doly, “A rapid alkaline extraction procedure for screening recombinant plasmid DNA”, (1979) Nucleic Acids Res 7(6), pp. 1513-1523. [cited by applicant]
Brown and Audet, “Current techniques for single-cell lysis”, (2008) J R Soc. Interface 5: S131-S138. [cited by applicant]
Brown et al. “Chemistry: The Central Science”, 12th ed. (2012) Pearson Education, Inc., Section 4.3, p. 125. [cited by applicant]
Brown et al. “Chemistry: The Central Science”, 12th ed. (2012) Pearson Education, Inc., Section 16.5, pp. 664-666. [cited by applicant]
Chomczynski and Rymaszewski, “Alkaline Polyethylene Glycol-Based Method for Direct PCR from Bacteria, Eukarvotic Tissue Samples, and Whole Blood”, (2006) BioTechniques, 40(4), pp. 454-458. [cited by applicant]
Darnell et al., “Whole mount in situ hybridization detection of mRNAs using short LNA containing DNA oligonucleotide probes”, (2010) RNA, 16(3): pp. 632-637. [cited by applicant]
Handbook Invitrogen user guide “Dynabeads® DNA DIRECT™ Universal for the Isolation of PCR-Ready Genomic DNA From Small Samples”, from Life Technologies, Catalog No. 63006, (2012) pp. 1-36. [cited by applicant]
Handbook Invitrogen user guide “Purelink™ HiPure Plasmid DNA Purification Kits for mini, midi and maxi preparation of plasmid DNA”, from Thermo Fischer Scientific, Catalog No. K2100-02-K2100-07, Revision B.0, Publicatio… [cited by applicant]
Islam et al. “A Review on Mascroscale and Microscale Cell Lvsis Methods”, (2017) Micromachines, 8: 83, pp. 1-27. [cited by applicant]
Klintschar and Neuhuber, “Evaluation of an Alkaline Lysis Method for the Extraction of DNA from Whole Blood and Forensic Stains for STR Analysis”, (2000) ASTM International J Forensic Sci, 45(3), pp. 669-673. [cited by applicant]
Machine translation of JP 2014-045689 A, 28 pages. [cited by applicant]
Merel et al. “Completely Automated Extraction of DNA from Whole Blood”, (1996) Clin Chem., 42(8), pp. 1285-1286. [cited by applicant]
Nelson and Cox, “Lehninger: Principles of Biochemistry”, 4th ed. (2004) W.H. Freeman, pp. 291, 314, and 315. [cited by applicant]
Notice of Opposition to a European Patent, for European Patent No. EP3814496, submitted Aug. 22, 2024, 44 pages. [cited by applicant]
Response to Examination Report during examination of the Opposed Patent dated May 25, 2022, 7 pages. [cited by applicant]
Rudbeck and Dissing, “Rapid, Simple Alkaline Extraction of Human Genomic DNA from Whole Blood, Buccal Epithelial Cells, Semen and Forensic Stains for PCR”, (1998) BioTechniques, 25(4), pp. 588-592. [cited by applicant]
Schrader et al. “PCR inhibitors—occurrence, properties and removal”, (2012) J Appl Microbiol, 113(5), pp. 1014-1026. [cited by applicant]
Truett et al. “Preparation of PCR-Quality Mouse Genomic DNA with Hot Sodium Hvdroxide and Tris (HotSHOT)”, (2000) BioTechniques, 29(1), pp. 52-54. [cited by applicant]
Examination Report issued Oct. 23, 2024, in counterpart Australian Application No. 2019294109. [cited by applicant]
Response to Opposition filed Jan. 3, 2025, in counterpart European Application No. 19734637.2. [cited by applicant]
Notice of Reasons for Rejection issued May 13, 2024, in counterpart Japanese Application No. 2020-572965. [cited by applicant]